TNKS and cancer: By using two distinct and structurally unrelated inhibitors, including a new investigational compound for which we provide original structural, pharmacological, and biochemical characterization, we found that abrogation of TNKS/2 activity markedly weakened cancer cell motility owing to perturbation of recognized microtubule-dependent routes that govern cell-oriented locomotion.